Skip to main content
Merck Phase 3 trial shows survival benefit
Image for illustrative purposes only. Not a real photo.

Merck Phase 3 trial shows survival benefit

By

Key points

  • Merck (NYSE:MRK) reported that its Phase 3 TroFuse-015 trial met its primary overall survival endpoint, with sacituzumab tirumotecan (sac-TMT) outperforming standard treatment in advanced gastroesophageal adenocarcinoma.
  • The investigational drug did not meet the secondary progression-free survival endpoint, although objective response rates nominally favoured sac-TMT.
  • TroFuse-015 is the second positive Phase 3 result in Merck's TroFuse programme, which currently includes 18 ongoing global Phase 3 trials across multiple cancer types.

Merck (NYSE:MRK) announced that its Phase 3 TroFuse-015 trial met its primary overall survival endpoint, with investigational drug sacituzumab tirumotecan improving survival compared with standard treatment in patients with advanced gastroesophageal adenocarcinoma.

The study involved patients with locally advanced unresectable or metastatic disease who had received at least two previous lines of systemic therapy, with Merck describing the results as the first overall survival benefit demonstrated by a TROP2-directed antibody-drug conjugate in this population in a global Phase 3 trial.

"Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC," said Dr. Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories.

However, sac-TMT did not meet the secondary progression-free survival endpoint assessed by blinded independent central review, while objective response rates nominally favoured the drug but were not formally tested under the prespecified analysis plan.

Following the announcement, Merck shares were down 3.04% at US$133.59 in intraday trading on November 20, 2026.

TroFuse-015 represents the second positive Phase 3 result from Merck's TroFuse clinical development programme, which currently includes 18 ongoing global Phase 3 studies evaluating sac-TMT across different cancer types and treatment settings.

The programme evaluates the investigational TROP2-directed antibody-drug conjugate across endometrial, bladder, breast, cervical, gastric, lung and ovarian cancers, with 14 of its 18 studies pursuing potential first-in-class treatment opportunities.


Frequently asked questions